USD
+$0.00
(+0.00%
)At Close (As of Dec 9, 2025)
$80.34M
Market Cap
-
P/E Ratio
-1.25
EPS
$1.11
52 Week High
$0.44
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Total Assets | $220M |
| Total Current Assets | $180M |
| Cash And Cash Equivalents At Carrying Value | $56M |
| Cash And Short Term Investments | $56M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $40M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $120M |
| Other Current Assets | $3.8M |
| Other Non Current Assets | - |
| Total Liabilities | $34M |
| Total Current Liabilities | $19M |
| Current Accounts Payable | $4.8M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $3.1M |
| Total Non Current Liabilities | $14M |
| Capital Lease Obligations | $17M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $17M |
| Other Current Liabilities | $11M |
| Other Non Current Liabilities | $116K |
| Total Shareholder Equity | $187M |
| Treasury Stock | - |
| Retained Earnings | -$498M |
| Common Stock | $8K |
| Common Stock Shares Outstanding | $88M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Adicet Bio, Inc. is an innovative biotechnology company focused on pioneering allogeneic gamma delta T cell therapies aimed at treating cancer and other serious diseases. Headquartered in Boston, Massachusetts, the company leverages its proprietary platform to develop novel immune-oncology solutions, positioning itself at the forefront of cell therapy advancements. With a robust pipeline of candidates in clinical development, Adicet Bio is dedicated to improving patient outcomes through its cutting-edge research and commitment to harnessing the immune system's potential.